Treatment of SAPHO with pamidronate

Courtney, Pamela; Hosking, David J.; Fairbairn, K. J.; Deighton, Chris

doi:10.1093/rheumatology/41.10.1196

Cited by 31 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also document clinical and radiologic improvement, in contrast to Courtney et al (5), who failed to show a difference in their patient's isotope scans after pamidronate treatment. Zoledronic acid is 2-3 orders of magnitude more potent than is pamidronate in bone resorption assays but shows a 3-fold greater renal tolerability (10).…”

Section: Discussionsupporting

confidence: 49%

Successful treatment of SAPHO syndrome with zoledronic acid

Kopterides¹,

Pikazis²,

Koufos³

2004

Arthritis & Rheumatism

View full text Add to dashboard Cite

The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a chronic, relapsing, inflammatory condition with skin and osteoarticular manifestations. Its etiology remains unclear, and various treatment regimens with steroids and nonsteroidal antiinflammatory drugs frequently fail to control the disease, while exposing patients to the side effects of these drugs. Because the SAPHO syndrome manifests as a destructive inflammatory bone disease, use of bisphosphonates that possess antiosteoclastic and probably antiinflammatory properties has been suggested to be helpful. To our knowledge, this is the first reported case of successful treatment with zoledronic acid of SAPHO syndrome that was resistant to conventional treatment.

show abstract

Section: Discussionsupporting

confidence: 49%

Successful treatment of SAPHO syndrome with zoledronic acid

Kopterides¹,

Pikazis²,

Koufos³

2004

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Using antibiotics as sole therapy has led to unpredictable results and has not been successful in most cases 2,8,15,16,28,30,[33][34][35] . The efficacy of many other medications has not been fully determined 8,9,12,28,34,35 ; including immunomodulating drugs such as methotrexate, cyclosporine, leflunomide; antitumor necrosis factor therapy using infliximab, sulfasalazine, calcitonin, and bisphosphonates 6,14,16,19,29,30 . Hyperbaric oxygen therapy has been used as adjunctive treatment with variable success 2,9,16,19,33 .…”

Section: Discussionmentioning

confidence: 99%

SAPHO syndrome with TMJ involvement: review of the literature and case presentation

McPhillips

Wolford

Rodrigues

2010

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…Otherwise, non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying anti‐rheumatic drugs (DMARDs) (i.e. methotrexate, cyclosporin, sulfasalazine), colchicines, corticosteroids (oral or local injection), and recently bisphosphonates and pamidronates are used for SAPHO syndrome . Bisphosphonates have anti‐osteoclastic effects, and pamidronate has anti‐inflammatory effects by suppressing the production of pro‐inflammatory cytokines .…”

Section: Therapymentioning

confidence: 99%

Pustulotic arthro‐osteitis associated with palmoplantar pustulosis

Yamamoto

2013

The Journal of Dermatology

View full text Add to dashboard Cite

Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles of middle-aged women. PPP frequently develops or exacerbates following focal infections, such as tonsillitis, odontogenic infection and sinusitis, either with or without arthralgia and/or extra-palmoplantar lesions. Pustulotic arthro-osteitis (PAO) is a joint comorbidity of PPP, most often affecting the anterior chest wall. PAO is sometimes regarded as the same entity as synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome, and may be a subtype or incomplete type of SAPHO syndrome; however, there are several differences. In Japanese patients, PPP with PAO is frequently seen, whereas SAPHO syndrome in the true meaning is rare. A difference of incidence depending on race suggests that different genetic backgrounds may be responsible for susceptibility to these disorders. Bacterial infection, especially Propionibacterium acnes, is suggested to play an important role in the pathogenesis of SAPHO syndrome. P. acnes is responsible for acne, however, bacterium is unassociated with PPP skin lesions which are characterized by sterile pustules. On the other hand, PAO is frequently triggered by focal infection, and treatment of focal infection results in dramatic effects on the release of joint pain. This paper reviews current insights into the clinicopathophysiology of PAO, and discusses its possible mechanisms in comparison with SAPHO syndrome.

show abstract

Treatment of SAPHO with pamidronate

Cited by 31 publications

References 5 publications

Successful treatment of SAPHO syndrome with zoledronic acid

Successful treatment of SAPHO syndrome with zoledronic acid

SAPHO syndrome with TMJ involvement: review of the literature and case presentation

Pustulotic arthro‐osteitis associated with palmoplantar pustulosis

Contact Info

Product

Resources

About